A Phase 1 Study to Evaluate the Pharmacokinetic Profile of ACH-0144471 Following Administration of Modified Release Prototype Formulations in Healthy Subjects

Trial Profile

A Phase 1 Study to Evaluate the Pharmacokinetic Profile of ACH-0144471 Following Administration of Modified Release Prototype Formulations in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2018

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
  • Focus Pharmacokinetics
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 25 May 2018 Status changed from active, no longer recruiting to completed.
    • 26 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Dec 2017 According to an Achillion Pharmaceuticals media release, interim results from this trial are anticipated during the second quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top